Table 3.
Cell cycle analysis after treatments
| Cell line | Treatments | Cell cycle distribution (G1, S, G2) | ||
|---|---|---|---|---|
| G1 phase (%) | S phase(%) | G2 phase (%) | ||
| GBC‐SD | Ad5‐TFPI‐2 | 57.15 ± 4.18 | 21.22 ± 1.61 | 21.63 ± 5.16 |
| Ad5‐GFP | 56.92 ± 3.37 | 24.54 ± 0.93 | 18.54 ± 3.6 | |
| PBS | 54.63 ± 3.18 | 29.80 ± 2.60 | 15.57 ± 1.11 | |
| SGC‐996 | Ad5‐TFPI‐2 | 57.68 ± 4.69 | 27.64 ± 3.03 | 14.68 ± 2.28 |
| Ad5‐GFP | 60.26 ± 4.26 | 24.75 ± 2.55 | 14.99 ± 3.85 | |
| PBS | 60.37 ± 4.65 | 22.47 ± 2.66 | 17.16 ± 2.13 | |
| NOZ | Ad5‐TFPI‐2 | 56.65 ± 3.33 | 29.34 ± 3.53 | 14.01 ± 1.68 |
| Ad5‐GFP | 56.87 ± 2.62 | 28.54 ± 1.33 | 14.59 ± 1.31 | |
| PBS | 51.84 ± 3.38 | 27.70 ± 1.47 | 20.46 ± 1.91 | |
Adenovirus‐mediated gene transfer of tissue factor pathway inhibitor‐2 (Ad5‐TFPI‐2) did not change cell cycle distribution of all three cell lines (P > 0.05).